Vera Therapeutics, Inc. (VERA)

42.87 -0.57 (-1.31%) As of 11:17AM EDT. Market open.

Vera Therapeutics, Inc.

8000 Marina Boulevard
Suite 120
Brisbane, CA 94005
United States
650 770 0077
https://veratx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 51

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Marshall W. Fordyce M.D.	Founder, President, CEO & Director	910.14k	N/A	1975
Mr. Sean P. Grant M.B.A.	Chief Financial Officer	642k	N/A	1985
Mr. Joseph R. Young M.B.A.	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1973
Mr. Julien E. Capers J.D.	VP & Head of Legal	N/A	N/A	N/A
Ms. Kelly Rauber	VP & Head of Human Resources	N/A	N/A	N/A
Mr. Tom Doan	Senior Vice President of Development Operations	N/A	N/A	1972
Ms. Lauren Frenz	Chief Business Officer	N/A	N/A	1985
Dr. Neeraj Pakala M.B.A., Ph.D.	Senior VP and Head of Product Development & Manufacturing	N/A	N/A	N/A
Dr. Kerry Cooper M.D.	Senior Vice President of Medical Affairs	N/A	N/A	N/A
Dr. Robert M. Brenner M.D.	Chief Medical Officer	N/A	N/A	1968

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Corporate governance

Vera Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.